We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-9.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.23B
AUM Growth
-$307M
Cap. Flow
+$10.8M
Cap. Flow %
0.88%
Top 10 Hldgs %
46.8%
Holding
78
New
13
Increased
11
Reduced
35
Closed
8

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$23.1M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$19.1M
3
TWST icon
Twist Bioscience
TWST
+$15.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$14.1M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$13.3M

Top Sells

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$40.7M
2
NKTR icon
Nektar Therapeutics
NKTR
+$33.1M
3
TSRO
TESARO, Inc.
TSRO
+$16.8M
4
OMER icon
Omeros
OMER
+$14M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$8.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
76
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-500,000
Closed -$2.9M
AKCA
77
PUT
DELISTED
Akcea Therapeutics Inc
AKCA
– –
-100,000
Closed -$3.5M
ONSIW
78
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
– –
-416,666
Closed -$9K
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Cormorant Asset Management held 78 positions worth $1.23B, down 20% from $1.54B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q4 2018 filing shows 13 new, 11 increased, 35 reduced and 8 closed positions. Its largest new stake was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M. The largest sale was Autolus Therapeutics, an estimated $40.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2018 buy was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M.
  • Cormorant Asset Management added most to argenx in Q4 2018, an estimated $23.1M increase.
  • Cormorant Asset Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $33.1M.
  • Cormorant Asset Management fully exited Autolus Therapeutics in Q4 2018, selling an estimated $40.7M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $1.23B portfolio in Q4 2018.
  • Cormorant Asset Management opened 13 new positions and closed 8 in Q4 2018.
  • Cormorant Asset Management's portfolio value fell 20% quarter-over-quarter to $1.23B.

Based on Cormorant Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.